%PDF-1.7
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2021-09-20T16:00:03-04:00
2021-09-20T16:00:07-04:00
2021-09-20T16:00:07-04:00
Adobe InDesign 16.1 (Macintosh)
uuid:bb6d9d8d-1628-c345-924e-6186740d1157
xmp.did:9c3cf535-2568-4a8c-93bc-e4108570899b
xmp.id:0d59ed93-dac2-4e8f-bfc5-74bfbb15ebdb
proof:pdf
xmp.iid:8a4e5948-958a-4a10-ba81-94b2b3dc3518
xmp.did:8a4e5948-958a-4a10-ba81-94b2b3dc3518
xmp.did:9c3cf535-2568-4a8c-93bc-e4108570899b
default
converted
from application/x-indesign to application/pdf
Adobe InDesign 16.1 (Macintosh)
/
2021-09-20T16:00:03-04:00
application/pdf
Adobe PDF Library 15.0
False
endstream
endobj
3 0 obj
<>
endobj
5 0 obj
</LastModified/NumberofPages 1/OriginalDocumentID/PageTransformationMatrixList<0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<0 251>>/PageWidthList<0 612.0>>>>>>/Resources<>/ExtGState<>/Font<>/ProcSet[/PDF/Text/ImageC/ImageI]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
6 0 obj
</LastModified/NumberofPages 1/OriginalDocumentID/PageTransformationMatrixList<0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<0 389>>/PageWidthList<0 612.0>>>>>>/Resources<>/ExtGState<>/Font<>/ProcSet[/PDF/Text/ImageC/ImageI]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
27 0 obj
<>stream
q
0 0 612 792 re
W n
q
/GS0 gs
0 TL/Fm0 Do
Q
Q
BT
/CS0 cs 1 scn
/GS1 gs
/TT0 1 Tf
14 0 0 14 31.8 749 Tm
[(C)12 (OMPREHENSIVE SER)12.1 (VICES)]TJ
/CS1 cs 0 0 0 1 scn
/GS2 gs
/TT1 1 Tf
10 0 0 10 31.8 734 Tm
[(T)18 (he Gr)18 (eenle)6.1 (af)-24 ( P)48 (r)18 (oduct Quality)36.1 (,)30 ( Manufacturing,)30.1 ( and C)12 (ompliance )24 (T)96 (e)6 (am uses its combined depth of)-23.8 ( knowledge and )]TJ
0 -1.5 Td
[(br)18 (e)6 (adth of)-23.9 ( skill to pr)18 (ovide the following compr)18.2 (ehensive services:)]TJ
6.544 -35.991 Td
(Greenleaf\222s regulatory experts demonstrate unmatched levels of skill \
in their specialties of quality and )Tj
/C2_0 1 Tf
0 -1.3 Td
<0046005200500053004F004C0044005100460048001100030037004B004800030046005200500045004C005100480047000300440046004B004C004800590048005000480051005700560003004400510047000300560058004500560057004400510057004C0044004F0003005400580044004F004C0193004600440057004C00520051005600030052004900030057004B00480003002A0055004800480051004F0048004400490003005700480044005000030048005100440045004F0048000300440003>Tj
/TT1 1 Tf
0 -1.3 Td
(cross-functional, full-service engagement that delivers best-in-class in\
sight and consultations. )Tj
/TT0 1 Tf
14 0 0 14 30.976 354.8079 Tm
[(EXPER)12 (T)]TJ
0.845 -1.357 Td
(TEAM)Tj
ET
/CS0 CS 1 SCN
4 M
/GS1 gs
q 1 0 0 1 90.8 365.808 cm
0 0 m
0 -32.7 l
S
Q
BT
/GS2 gs
10 0 0 10 67.2 686.9606 Tm
(Compliance Assessments)Tj
/TT1 1 Tf
9.5 0 0 9.5 67.2 672.9606 Tm
(Greenleaf works with life science entities to )Tj
0 -1.474 Td
(evaluate and strengthen compliance functions with )Tj
0 -1.474 Td
(an eye toward optimizing processes, mitigating )Tj
0 -1.474 Td
(risks, and creating a culture of compliance, while )Tj
0 -1.474 Td
(continuing to meet business objectives.)Tj
/TT0 1 Tf
10 0 0 10 353.76 686.9606 Tm
(Inspection Readiness)Tj
/TT1 1 Tf
9.5 0 0 9.5 353.76 672.9606 Tm
(An FDA inspection is a noteworthy moment )Tj
0 -1.474 Td
(for any regulated company. Greenleaf experts )Tj
0 -1.474 Td
(strengthen clients\222 readiness for FDA preapproval )Tj
0 -1.474 Td
(and surveillance inspections through consulting, )Tj
0 -1.474 Td
(training, audits, and mock inspections.)Tj
/TT0 1 Tf
10 0 0 10 67.2 590.9606 Tm
(Compliance Remediation)Tj
/TT1 1 Tf
9.5 0 0 9.5 67.2 576.9606 Tm
(Greenleaf experts bring an unmatched level of )Tj
0 -1.474 Td
(credibility and trust when interacting with the )Tj
0 -1.474 Td
(FDA. The team has the experience and insight )Tj
0 -1.474 Td
(to successfully guide companies along the )Tj
0 -1.474 Td
(remediation pathway.)Tj
/TT0 1 Tf
10 0 0 10 353.76 590.9606 Tm
(FDA Communications)Tj
/TT1 1 Tf
9.5 0 0 9.5 353.76 576.9606 Tm
(Greenleaf\222s best-in-class experts bring value to )Tj
0 -1.474 Td
(any communication with the FDA, including formal )Tj
0 -1.474 Td
(regulatory communication, in-person meetings, )Tj
0 -1.474 Td
(and responses to compliance actions and )Tj
0 -1.474 Td
(regulatory correspondence.)Tj
/TT0 1 Tf
10 0 0 10 67.2 494.9606 Tm
(Consultation, Training & )Tj
0 -1.4 Td
(Regulatory Guidance)Tj
/TT1 1 Tf
9.5 0 0 9.5 67.2 466.9606 Tm
(Greenleaf delivers insight and guidance that )Tj
0 -1.474 Td
(help clients achieve business and regulatory )Tj
0 -1.474 Td
(objectives. The team also develops and delivers )Tj
0 -1.474 Td
(training on a variety of regulatory subjects.)Tj
/TT0 1 Tf
10 0 0 10 353.76 494.9606 Tm
(GCP Services)Tj
/TT1 1 Tf
9.5 0 0 9.5 353.76 480.9606 Tm
(Greenleaf specialists use a risk-based )Tj
0 -1.474 Td
(methodology to develop and improve clinical )Tj
/C2_0 1 Tf
0 -1.474 Td
<005400580044004F004C0057005C00030056005C0056005700480050005600110003002500480046004400580056004800030057004B0048005500480003004C0056000300510052000300520051004800100056004C005D0048001001930057005600100044004F004F0003>Tj
/TT1 1 Tf
0 -1.474 Td
(approach to GCP compliance, each solution is built )Tj
/C2_0 1 Tf
0 -1.474 Td
<0057005200030193005700030057004B00480003005700440055004A004800570048004700030051004800480047005600030052004900030057004B004800030046004F004C0048005100570011>Tj
ET
q
32.08 667.659 21.113 27.469 re
W n
q
/GS1 gs
21.1137318 0 0 27.5056506 32.0792694 667.6589612 cm
/Im0 Do
Q
Q
q
33.84 573.487 19 24.72 re
W n
q
/GS1 gs
19 0 0 25.0750408 33.8400116 573.4249592 cm
/Im1 Do
Q
Q
q
31.44 478.624 24 23.975 re
W n
q
/GS1 gs
23.9999993 0 0 24.0557484 31.4400024 478.6241833 cm
/Im2 Do
Q
Q
q
318.04 478.042 23.999 23.886 re
W n
q
/GS1 gs
23.9999986 0 0 23.8854401 318.0400391 478.0424163 cm
/Im3 Do
Q
Q
q
317.368 578.002 24 20.206 re
W n
q
/GS1 gs
23.9999993 0 0 20.7575052 317.3678284 578.0017111 cm
/Im4 Do
Q
Q
q
318.28 694.208 21.48 -21.04 re
W n
q
/GS1 gs
21.4799988 0 0 21.3599999 318.2800293 673.1678322 cm
/Im5 Do
Q
Q
/CS1 CS 0 0 0 0 SCN
2 w
/GS1 gs
q 1 0 0 1 61.2 694.2078 cm
0 0 m
0 -80.4 l
S
Q
q 1 0 0 1 61.24 598.2078 cm
0 0 m
0 -79.44 l
S
Q
q 1 0 0 1 61 502.2078 cm
0 0 m
0 -79.44 l
S
Q
q 1 0 0 1 348 694.2078 cm
0 0 m
0 -80.4 l
S
Q
q 1 0 0 1 348.04 598.2078 cm
0 0 m
0 -79.44 l
S
Q
q 1 0 0 1 347.8 502.2078 cm
0 0 m
0 -79.44 l
S
Q
BT
/CS0 cs 1 scn
/TT0 1 Tf
10 0 0 10 78.0073 172 Tm
(KRISTEN GRUMET)Tj
/CS1 cs 0 0 0 1 scn
/GS2 gs
8 0 0 8 78.0073 162 Tm
(Senior VP, Regulatory Compliance)Tj
0.86 0.75 0.56 0.72 scn
/GS1 gs
/TT1 1 Tf
0 -1.25 Td
(25-year compliance career, including role )Tj
/C2_0 1 Tf
0 -1.25 Td
<004400560003004400510003002900270024000301930048004F00470003004C00510059004800560057004C004A004400570052005500030056005300480046004C0044004F004C005D004C0051004A0003004C00510003>Tj
/TT1 1 Tf
0 -1.25 Td
(medical devices.)Tj
/CS0 cs 1 scn
/TT0 1 Tf
10 0 0 10 366.5162 298.5 Tm
(CYNTHIA SCHNEDAR)Tj
/CS1 cs 0 0 0 1 scn
/GS2 gs
8 0 0 8 366.5162 288.5 Tm
(Principal, Regulatory Compliance)Tj
0.86 0.75 0.56 0.72 scn
/GS1 gs
/TT1 1 Tf
0 -1.25 Td
(25-year compliance career, including )Tj
0 -1.25 Td
(serving as director of the FDA\222s drug )Tj
/C2_0 1 Tf
0 -1.25 Td
<0046005200500053004F004C00440051004600480003005200490193004600480011>Tj
ET
q
320.4 258.538 38 47.2 re
W n
q
39.4042541 0 0 48.5106368 319.3648487 257.4572587 cm
/Im6 Do
Q
Q
BT
/CS0 cs 1 scn
/TT0 1 Tf
10 0 0 10 78.16 235.1279 Tm
(DAVID ELDER)Tj
/CS1 cs 0 0 0 1 scn
/GS2 gs
8 0 0 8 78.16 225.1279 Tm
(Principal, Regulatory Compliance)Tj
0.86 0.75 0.56 0.72 scn
/GS1 gs
/TT1 1 Tf
0 -1.25 Td
(23-year veteran of the FDA with prominent roles )Tj
0 -1.25 Td
(in domestic and foreign inspections, recalls and )Tj
0 -1.25 Td
[(emer)18 (gencies, and compliance actions.)]TJ
ET
q
32.04 242.16 38 -47.2 re
W n
q
38.2814897 0 0 48.2519965 32.0400162 193.9080072 cm
/Im7 Do
Q
Q
BT
/CS0 cs 1 scn
/TT0 1 Tf
10 0 0 10 366.52 235.0079 Tm
(KALAH AUCHINCLOSS)Tj
/CS1 cs 0.86 0.75 0.56 0.72 scn
8 0 0 8 366.52 225.0079 Tm
(Exec. VP, Regulatory Compliance )Tj
/TT1 1 Tf
0 -1.25 Td
(15 years of experience on Capitol Hill, )Tj
0 -1.25 Td
(in the private sector, and at the FDA, )Tj
0 -1.25 Td
(including role as Deputy Chief of Staff.)Tj
ET
q
320.44 195.02 38.001 47.2 re
W n
q
39.000001 0 0 48.4595757 320.4400024 193.940403 cm
/Im8 Do
Q
Q
BT
/CS0 cs 1 scn
/TT0 1 Tf
10 0 0 10 78.0874 298.5 Tm
(JOHN TAYLOR)Tj
/CS1 cs 0 0 0 1 scn
/GS2 gs
8 0 0 8 78.0874 288.5 Tm
(President and )Tj
/C2_1 1 Tf
0 -1.25 Td
<00330055004C00510046004C00530044004F000F00030026005200500053004F004C004400510046004800030009000300350048004A0058004F0044005700520055005C00030024004900490044004C00550056>Tj
0.86 0.75 0.56 0.72 scn
/GS1 gs
/C2_0 1 Tf
0 -1.25 Td
<00290052005500500048005500030029002700240003005600480051004C0052005500030052004901930046004C0044004F0003004B0048004F00470003004B004C004A004B00100053005500520193004F00480003005300520056004C0057004C0052005100560003004400570003>Tj
/TT1 1 Tf
0 -1.25 Td
(the Agency and senior leadership roles within industry.)Tj
ET
q
32.04 258.628 38 47.201 re
W n
q
39.000001 0 0 48.4595757 31.2014866 257.5479927 cm
/Im9 Do
Q
Q
BT
/CS0 cs 1 scn
/TT0 1 Tf
10 0 0 10 366.5 171.1679 Tm
(GRACE MCNALLY)Tj
/CS1 cs 0 0 0 1 scn
/GS2 gs
8 0 0 8 366.5 161.1679 Tm
(Senior VP, Regulatory Compliance)Tj
0.86 0.75 0.56 0.72 scn
/GS1 gs
/TT1 1 Tf
0 -1.25 Td
(33-year FDA career, including experience as )Tj
0 -1.25 Td
(an investigator and leadership of many drug )Tj
0 -1.25 Td
(cGMP and quality initiatives.)Tj
ET
q
320.4 131.365 37.88 47.201 re
W n
q
37.9999996 0 0 48.8977108 320.2799988 130.3580265 cm
/Im10 Do
Q
Q
BT
/CS0 cs 1 scn
/TT0 1 Tf
10 0 0 10 77.68 107.6879 Tm
(BRITTANY MILBY)Tj
/CS1 cs 0 0 0 1 scn
/GS2 gs
/C2_1 1 Tf
8 0 0 8 77.68 97.6879 Tm
<0028005B00480046001100030027004C0055004800460057005200550003005200490003003200530048005500440057004C005200510056000F0003>Tj
/TT0 1 Tf
0 -1.25 Td
(Regulatory Compliance)Tj
0.86 0.75 0.56 0.72 scn
/GS1 gs
/TT1 1 Tf
0 -1.25 Td
(Close to a decade of experience in pharmaceutical )Tj
0 -1.25 Td
(marketing, communications, and event planning.)Tj
ET
q
32.04 67.188 38 47.5 re
W n
q
39.000001 0 0 49.5382991 31.7291088 66.1802297 cm
/Im11 Do
Q
Q
q
32.04 178.408 38 -47.192 re
W n
q
38.4400002 0 0 47.8721269 31.9400024 130.53571 cm
/Im12 Do
Q
Q
BT
/CS0 cs 1 scn
/TT0 1 Tf
-0.024 Tw 10 0 0 10 319.8 107.5 Tm
[(ADDITIONAL)24 ( TEAM )-23.9 (MEMBERS)]TJ
/CS1 cs 0.86 0.75 0.56 0.72 scn
0 Tw 8 0 0 8 319.8 96.5 Tm
[(Liz Oestr)18 (eich)]TJ
/TT1 1 Tf
-0.03 Tc 0.03 Tw (, )Tj
/C2_2 1 Tf
0 Tc 0 Tw [<0039004C0046004800030033>48 <0055>12 <00480056004C0047004800510057000F>30 <00030035>12.1 <0048004A0058004F0044>10 <005700520055005C00030026>12 <005200500053004F004C0044005100460048>]TJ
/TT0 1 Tf
0 -1.375 Td
(Maria Bonner)Tj
/TT1 1 Tf
-0.03 Tc 0.03 Tw (, )Tj
/C2_2 1 Tf
0 Tc 0 Tw [<0039004C0046004800030033>48 <0055>12 <00480056004C0047004800510057000F>30.1 <00030035>12 <0048004A0058004F0044>10 <005700520055005C00030026>12 <005200500053004F004C0044005100460048>]TJ
/TT0 1 Tf
0 -1.375 Td
(Madeleine Giaquinto)Tj
/TT1 1 Tf
-0.03 Tc 0.03 Tw (, )Tj
/C2_2 1 Tf
0 Tc 0 Tw [<0030004400510044004A00480055>36 <000F>30 <00030035>12 <0048004A0058004F0044>10 <005700520055005C0003>18.1 <00240049>18 <00490044004C00550056>]TJ
/TT0 1 Tf
0 -1.375 Td
[(Laur)13 (a Bar)12.1 (tee)]TJ
/TT1 1 Tf
-0.03 Tc 0.03 Tw (, )Tj
/C2_2 1 Tf
0 Tc 0 Tw [<0027004C0055>12 <00480046005700520055000300520049>-23.9 <00030032005300480055>12 <0044>10 <0057004C005200510056000F>30 <00030035>12 <0048004A0058004F0044>10 <005700520055005C00030026>12.1 <005200500053004F004C0044005100460048>]TJ
ET
/CS0 cs 1 scn
0 0 612 42.208 re
f
q
144.0000018 0 0 21.3226616 387.5999756 10.4852226 cm
/Im13 Do
Q
BT
/CS1 cs 0 0 0 0 scn
/C2_1 1 Tf
0.05 Tc -0.05 Tw 10 0 0 10 30 16.6079 Tm
[<005A005A005A>36 <0011004A0055>18 <004800480051004F0048>6 <00440049004B0048>6 <0044004F0057004B0011004600520050>]TJ
ET
endstream
endobj
28 0 obj
<>
endobj
37 0 obj
<>/ExtGState<>>>/Subtype/Form>>stream
/CS0 cs 0 0 0 0.12 scn
/GS0 gs
0 392.608 611.219 399.392 re
f
endstream
endobj
38 0 obj
<>stream
Hm[`R(isH$@sЊ.7PaͶ;hW?C層N w{M3i4{w@kjk쿹6UArcSL-Z:HHm5A{a+
!
պ'jK 㓴GZm"]/NMLy']3yN͚1tC^5=ʡo>tLHr9ksC\n5SIA>.ˤ;:CK6S?6'ړZn*kWt/oft7}0lKU!fL%55c"6ftGՇa t>kƜHw*a˥NbdXHaU`U!m.^O[Kw;߽T؋k
RxrC̦-WBItNztT[Ӓ@S͚1-D>GSY9YԜ#P>bn2+XGB},5Gªo%Mަ?YX]w쐑sO6[v[
ē8goUl5WmEjPDv_ٔu0Vaxo5sm3:{1߷|80<9dܯ)osb!τIͺ^ף15DŽWA_xo9s7-6D6ğ2̝d>EHgbOjv|.ad_Yeya[;_*Ɯ2q 9siE)܈ynr/ΔQ Ew]
?1,ܳ~ٻ.5YMÓc5v+_W-N1n C:[k|+cJtYu[g!fKv9[nCTo=EPRCyY~xqW._mW0_qf\|5ɉQYJ۬~.69#{qr']i(?<]#JSz
P̰Lԯ7fL/3OKG']eb>l+kLL^&^$w
Ӳ}g5r~%;r|%*qЊFvkKѶ+]bRa=,8m0).[>v+iZ¤QtB8>/NF5Ed'[jtr&:?s":%1>x`B,+醗Mz˪Ώy]e3=.FzkU۾({\/z㢤^yiX"j⤧ۦz}i
.ڻTMbt7p#FQZVCz5MmaMݮC"=]2lڳ
B#=]"\ҽkV#jYCؤJەt>´t}\hT/!:Kz^N4 (@IOK#j&=]?v6\CT6Wj%=]_̥hJIOWMG{Vh&ņ)W[!]pHziѵD65H[uK~:<"v.Qve\UC*F%~Mzk8[eA_l^~p^A6tW{EpiYC6 ty=5e;BT+!lZ6ɖGh
¦%lSdD
¦&lGu]qVMGj,+rC6=asS/a2XʶnC]!l}a?i
H-q:J\a+xV
[((Qh
[[79lcG9'ߒ5:lʶA} l}l[ʔmaKm l)S
-eʶL6)2e@Rl[ʔmaKm l)S
-eʶL6)2e@Rl[ʔmaKm l)S
-eʶL6)2e@Rl[ʔmaKm l)S
-eʶ]ZK.xx&1m$isPAy
A
l6`
la6A
l6`
la6A
l6`
la6A
l6`
la6A
l6`
la6A
l6`
la6A
l6`
la6A
l6`
la6A
¶RD!l+f#Kא&m|"tIBؖEua{Qg?!lT!lt5A^,GgR8|4xGҰJW+iake}NK1)lGRt=6m6 L#l_t3"v4S{V&Kb6H v?m<Hw v?䰹PcOpؼ^ݦڊp> v?ܰ
:
=@~aVaJz[ϣ0GR]#v?̰y
BNjKXsgU#v?İnMn#Lm{o>,7W&v4X]5b[A۫F~Xa
PGu#v?iRw!Mh@/A5b .}WנMh@/B5bC 1}ʠW